Intermediate Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis

Abstract Different doses of low-molecular-weight heparin (LMWH) are registered and used for thrombosis prophylaxis. We assessed benefits and harms of thrombosis prophylaxis with a predefined intermediate-dose LMWH compared with placebo or no treatment in patients at risk of venous thromboembolism (VTE). We performed a systematic review with meta-analyses and trial sequential analyses (TSA) following The Cochrane Handbook for Systematic Reviews of Interventions. Medline, Cochrane CENTRAL, Web of Science, and Embase were searched up to December 2018. Trials were evaluated for risk of bias and quality of evidence was assessed following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seventy randomized trials with 34,046 patients were included. Eighteen (26%) had overall low risk of bias. There was a small statistically significant effect of LMWH on all-cause mortality (risk ratio [RR]: 0.96; TSA-adjusted confidence interval [TSA-adjusted CI]: 0.94–0.98) which disappeared in sensitivity analyses excluding ambulatory cancer patients (RR: 0.99; TSA-adjusted CI: 0.84–1.16). There was moderate-quality evidence for a statistically significant beneficial effect on symptomatic VTE (odds ratio [OR]: 0.59; TSA-adjusted CI: 0.53–0.67; number needed to treat [NNT]: 76; 95% CI: 60–106) and a statistically significant harmful effect on major bleeding (Peto OR: 1.66; TSA-adjusted CI: 1.31–2.10; number needed to harm [NNH]: 212; 95% CI: 142–393). There were no significant intervention effects on serious adverse events. The use of intermediate-dose LMWH for thrombosis prophylaxis compared with placebo or no treatment was associated with a small statistically significant reduction of all-cause mortality that disappeared in sensitivity analyses excluding trials that evaluated LMWH for anticancer treatment. Intermediate-dose LMWH provides benefits in terms of VTE prevention while it increases major bleeding.

[1]  H. Seo,et al.  Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial , 2018, JAMA surgery.

[2]  G. Chatellier,et al.  Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial , 2018, European Respiratory Journal.

[3]  X. Sun,et al.  Prevention of venous thromboembolism after resection of primary liver cancer with low molecular weight heparin and its association with P-selectin, lysosomal granule glycoprotein, platelet activating factor and plasma D-dimer. , 2018, European review for medical and pharmacological sciences.

[4]  Lara A. Kahale,et al.  Anticoagulation for people with cancer and central venous catheters. , 2018, The Cochrane database of systematic reviews.

[5]  Jian Zhang,et al.  Different combination strategies for prophylaxis of venous thromboembolism in patients: A prospective multicenter randomized controlled study , 2018, Scientific Reports.

[6]  L. Ek,et al.  Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Jakobsen,et al.  Trial Sequential Analysis in systematic reviews with meta-analysis , 2017, BMC Medical Research Methodology.

[8]  D. Rubens,et al.  Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. , 2017, Thrombosis research.

[9]  P. Licht,et al.  Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial , 2017, PloS one.

[10]  N. Kucher,et al.  Risk assessment models for venous thromboembolism in acutely ill medical patients , 2017, Thrombosis and Haemostasis.

[11]  R. Ahuja,et al.  An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin. , 2016, Burns : journal of the International Society for Burn Injuries.

[12]  K. Hood,et al.  Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Kahn,et al.  Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial. , 2016, Thrombosis research.

[14]  Seung-Jae Lim,et al.  Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty , 2016, Thrombosis and Haemostasis.

[15]  S. Alalaf,et al.  Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial , 2015, Journal of thrombosis and haemostasis : JTH.

[16]  B. Dörken,et al.  Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Eken,et al.  Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis , 2015, Intensive Care Medicine.

[18]  H. Kreder,et al.  A Double-Blind, Randomized Controlled Trial of the Prevention of Clinically Important Venous Thromboembolism After Isolated Lower Leg Fractures , 2015, Journal of orthopaedic trauma.

[19]  S. Kahn,et al.  Low-molecular-weight heparin to prevent postpartum venous thromboembolism , 2014, Thrombosis and Haemostasis.

[20]  Lara A. Kahale,et al.  Anticoagulation for people with cancer and central venous catheters. , 2014, The Cochrane database of systematic reviews.

[21]  S. Laporte,et al.  Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery , 2014, Thrombosis and Haemostasis.

[22]  S. Laporte,et al.  Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. , 2014, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[23]  A. Lazo-Langner,et al.  The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials , 2014, Journal of thrombosis and haemostasis : JTH.

[24]  M. Arora,et al.  Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an Indian perspective , 2014, Spinal Cord.

[25]  A. Cohen,et al.  Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.

[26]  S. Gates,et al.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. , 2014, The Cochrane database of systematic reviews.

[27]  R. Rosell,et al.  Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. , 2013, Thrombosis research.

[28]  R. Wolff,et al.  Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE , 2013 .

[29]  J. Segal,et al.  Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. , 2013, JAMA surgery.

[30]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[31]  D. Neuberg,et al.  Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study) , 2013, British journal of haematology.

[32]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[33]  Alshwia Hessa,et al.  C0327 Thromboembolism prophylaxis after cesarean section (PRO-CS) trial , 2012 .

[34]  Ethan M Balk,et al.  Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials , 2012, Annals of Internal Medicine.

[35]  A. Maraveyas,et al.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. , 2012, European journal of cancer.

[36]  K. Wani,et al.  Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience , 2012, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[37]  D. Heigener,et al.  Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[38]  C. Cimminiello,et al.  Low-molecular-weight heparin and mortality in acutely ill medical patients. , 2011, The New England journal of medicine.

[39]  Ya-wei Sun,et al.  [Enoxaparin for the prevention of post surgical pulmonary embolism]. , 2011, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[40]  M. Prins,et al.  Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Malkin,et al.  PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma , 2010, Journal of thrombosis and haemostasis : JTH.

[42]  Kristian Thorlund,et al.  Estimating required information size by quantifying diversity in random-effects model meta-analyses , 2009, BMC medical research methodology.

[43]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[44]  T. Gasser,et al.  THROMBOPROPHYLAXIS WITH DALTERPARINE FOR TRANSURETHRAL SURGERY, A DOUBLE-BLIND PLACEBO-CONTROLLED, RANDOMISED STUDY , 2009 .

[45]  N. Lo,et al.  Thromboembolic Prophylaxis for Total Knee Arthroplasty in Asian Patients: A Randomised Controlled Trial , 2009, Journal of orthopaedic surgery.

[46]  R. Buckley,et al.  Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. , 2009, The Journal of bone and joint surgery. British volume.

[47]  Kristian Thorlund,et al.  Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? , 2009, International journal of epidemiology.

[48]  Kristian Thorlund,et al.  Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. , 2009, International journal of epidemiology.

[49]  T. Ochi,et al.  Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin , 2008, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[50]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[51]  P. Novotny,et al.  Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. , 2007, Mayo Clinic proceedings.

[52]  S. Rosfors,et al.  Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: A randomized placebo-controlled, double-blind study , 2007, Acta orthopaedica.

[53]  M. Perpiñá-Tordera,et al.  Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa , 2006 .

[54]  D. Nauffal-Manzur,et al.  [Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?]. , 2006, Archivos de bronconeumologia.

[55]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Gates,et al.  Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. , 2004, American journal of obstetrics and gynecology.

[59]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[60]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[61]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[63]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[64]  D. Erni,et al.  Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin. , 2002, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[65]  A. Nicolaides,et al.  Venous Thrombosis from Air Travel: The LONFLIT3 Study , 2002, Angiology.

[66]  N. Rege,et al.  ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.

[67]  Y. Ho,et al.  Randomized, controlled trial of low molecular weight heparinvs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients , 1999, Diseases of the colon and rectum.

[68]  A. Iorio,et al.  Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. , 1998, The New England journal of medicine.

[69]  S. Yusuf,et al.  Overcoming the limitations of current meta-analysis of randomised controlled trials , 1998, The Lancet.

[70]  S. Yusuf,et al.  Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. , 1997, Controlled clinical trials.

[71]  C. Samama,et al.  Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. , 1997, British journal of anaesthesia.

[72]  F. Regan,et al.  Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. , 1996, International angiology : a journal of the International Union of Angiology.

[73]  J. Hirsh,et al.  Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. , 1996, Archives of internal medicine.

[74]  G. Bannister,et al.  Perioperative low-molecular-weight heparin. Is it effective and safe. , 1995, The Journal of bone and joint surgery. British volume.

[75]  K. Schmit-Neuerburg,et al.  Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg , 1995, The Lancet.

[76]  B. Hurson.  Limb-sparing surgery for patients with sarcomas. , 1995, The Journal of bone and joint surgery. British volume.

[77]  P. Bjerregaard,et al.  The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. , 1992, Clinical orthopaedics and related research.

[78]  W. Geerts,et al.  Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo , 1992, Thrombosis and Haemostasis.

[79]  P. Bjerregaard,et al.  Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. , 1991, The Journal of bone and joint surgery. British volume.

[80]  J. Hirsh,et al.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. , 1986, The New England journal of medicine.

[81]  Intermediate Dose LMWH for Thrombosis Prophylaxis , 2019 .

[82]  Tawan Intiyanaravut,et al.  Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial. , 2017, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[83]  M. Di Nisio,et al.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2014, The Cochrane database of systematic reviews.

[84]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[85]  Gordon H Guyatt,et al.  Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .

[86]  J. Thigpen.  Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer , 2012 .

[87]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[88]  A. Mickevičius,et al.  A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication. , 2010, Medicina.

[89]  J. Abraham.  The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[90]  K. Thorlund,et al.  Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. , 2008, Journal of clinical epidemiology.

[91]  R. Peters,et al.  The prophylaxis of medical patients for thromboembolism pilot study. , 2006, The American journal of medicine.

[92]  C. Samama,et al.  Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery † , 2002 .

[93]  Lain,et al.  A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .

[94]  A. Serradimigni,et al.  Prévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients) , 1990 .

[95]  R. Khalil,et al.  [Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)]. , 1990, La Revue de medecine interne.

[96]  M. Prins,et al.  Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. , 1989, Haemostasis.

[97]  M. Guillou,et al.  SUBCUTANEOUS ENOXAPARINE (LOVENOXR) VERSUS PLACEBO FOR PREVENTING DEEP VEIN THROMBOSIS (DVT) AFTER TRANSURETHRAL PROSTATECTOMY (TUP) , 1987, Thrombosis and Haemostasis.

[98]  C. Caulin,et al.  Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. , 1986, Haemostasis.